Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles
- 156 Downloads
The development of drug delivery systems able to induce accumulation of a prodrug or its metabolites in aggressive tumours is providing new approaches to achieve enhanced antitumor activity while reducing systemic toxicity. Only recently, the integration of core concepts from the field of biotechnology, nanotechnology and pharmacodynamics provided us with new insights on the possibility to identify anti-neoplastic targets and evaluate the theoretical feasibility of producing drug-incorporated hyaluronic acid (HA)-nanoparticles. Indeed, gliomas could represent the perfect proof of concept for nanoformulated drugs due to the intrinsic characteristics of those tumours: mainly, the high aggressiveness, poor prognosis and high degree of chemo-resistance. A thorough analysis of the current therapeutic armamentarium available for primary brain tumours, and the possible targets of HA-nanoparticles, is perfectly suited to better understand the opportunities provided by such...
KeywordsHyaluronic Acid Glioma Cell Malignant Glioma Primary Brain Tumour Glioma Invasion
We are grateful to Mrs Gloria Mognon for revision of the language and editing of the manuscript in its final version.
Conflict of interest
The author does not report any financial, personal or professional conflict of interest concerning the materials and methods used in this study or the findings specified in this paper.
- 5.Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.PubMedCrossRefGoogle Scholar